Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-α agonist, modulates carrageenan-induced paw edema in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 3, 2007, Pages 1137-1143

  D'Agostino, Giuseppe ^a   La Rana, Giovanna ^a   Russo, Roberto ^a   Sasso, Oscar ^a   Iacono, Anna ^a   Esposito, Emanuela ^a,b   Raso, Giuseppina Mattace ^a   Cuzzocrea, Salvatore ^b,c   Lo Verme, Jesse ^d   Piomelli, Daniele ^d   Meli, Rosaria ^a   Calignano, Antonio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 [2 [[(CYCLOHEXYLAMINO)CARBONYL](4CYCLOHEXYLBUTYL)AMINO]ETHYL]PHENYL]THIO] 2 METHYLPROPANOIC ACID; CARRAGEENAN; CYCLOOXYGENASE 2; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME DEGRADATION; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SPINAL CORD;

ANIMALS; CARRAGEENAN; CENTRAL NERVOUS SYSTEM; DRUG ADMINISTRATION ROUTES; EDEMA; INFLAMMATION; MICE; PALMITIC ACIDS; PPAR ALPHA;

EID: 34548068297     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.123265     Document Type: Article

References (40)

1. Auphan N, DiDonato JA, Rosette C, Helmberg A, and Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290.
2. Benani A, Heurtaux T, Netter P, and Minn A (2004) Activation of peroxisome proliferator-activated receptor alpha in rat spinal cord after peripheral noxious stimulation. Neurosci Lett 369:59-63.
3. Berdyshev E, Boichot E, Corbel M, Germain N, and Lagente V (1998) Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 63:PL125-PL129.
4. Bracey MH, Hanson MA, Masuda KR, Stevens RC, and Cravatt BF (2002) Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298:1793-1796.
5. Cadas H, di Tomaso E, and Piomelli D (1997) Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonyl phosphatidylethanolamine, in rat brain. J Neurosci 17:1226-1242.
6. Calignano A, La Rana G, Giuffrida A, and Piomelli D (1998) Control of pain initiation by endogenous cannabinoids. Nature 394:277-281.
7. Calignano A, La Rana G, and Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitoylethanolamide. Eur J Pharmacol 419:191-198.
8. Costa B, Conti S, Giagnoni G, and Colleoni M (2002) Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 137:413-420.
9. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
10. Delerive P, Fruchart JC, and Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169:453-459.
11. Desvergne B and Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20:649-688.
12. Devchand P, Keller H, Peters J, Vazquez M, Gonzalez F, and Wahli W (1996) The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384:39-43.
13. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, and Karin M (1997) A cytokine-esponsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388:548-554.
14. Di Rosa M (1974) Prostaglandins, leukocytes and non-steroidal anti-inflammatory drugs. Pol J Pharmacol Pharm 26:25-36.
15. Dolan S, Field LC, and Nolan AM (2000) The role of nitric oxide and prostaglandin signaling pathways in spinal nociceptive processing in chronic inflammation. Pain 86:311-320.
16. Forman BM, Chen J, and Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 94:4312-4327.
17. Garcia Leme J, Hamamura L, Leite MP, Rocha E, and Silva M (1973) Pharmacological analysis of the acute inflammatory process induced in the rat's paw by local injection of carrageenin and by heating. Br J Pharmacol 48:88-96.
18. George A, Marziniak M, Schafers M, Toyka KV, and Sommer C (2000) Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 88:267-275.
19. Genovese T, Mazzon E, Di Paola R, Cannavo G, Muia C, Bramanti P, and Cuzzocrea S (2005) Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. Exp Neurol 194:267-278.
20. Grilli M, Pizzi M, Memo M, and Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274:1383-1385.
21. Hammond DL and Yaksh TL (1981) Peripheral and central pathways in pain. Pharmacol Ther 14:459-475.
22. Ichitani Y, Shi T, Haeggstrom JZ, Samuelsson B, and Hokfelt T (1997) Increased levels of cyclooxygenase-2 mRNA in the rat spinal cord after peripheral inflammation: an in situ hybridization study. Neuroreport 8:2949-2952.
23. Iversen LL, Lee CM, Gilbert RF, Hunt S, and Emson PC (1980) Regulation of neuropeptide release. Proc R Soc Lond B Biol Sci 210:91-111.
24. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A 91:7355-7359.
25. Kostadinova R, Wahli W, and Michalik L (2005) PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 12:2995-3009.
26. Lee KM, Kang BS, Lee HL, Son SJ, Hwang SH, Kim DS, Park JS, and Cho HJ (2004) Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci 19:3375-3381.
27. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, and Piomelli D (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15-29.
28. Lo Verme J, Russo R, La Rana G, Fu J, Farthing J, Raso G, Meli R, Hohmann A, Calignano A, and Piomelli D (2006) Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated recepto-α. J Pharmacol Exp Ther 319:1051-1061.
29. Maihöfner C, Tegeder I, Euchenhofer C, deWitt D, Brune K, Bang R, Neuhuber W, and Geisslinger G (2000) Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord. Neuroscience 101:1093-1108.
30. Mazzari S, Canella R, Petrelli L, Marcolongo G, and Leon A (1996) N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 300:227-236.
31. Moreno S, Farioli-Vecchioli S, and Ceru MP (2004) Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 123:131-145.
32. Posadas I, Bucci M, Roviezzo F, Rossi A, Parente L, Sautebin L, and Cirino G (2004) Carrageenan-induced mouse paw oedema is biphasic, age-weight dependent and displays differential nitric oxide cyclooxygenase-2 expression. Br J Pharmacol 142:331-338.
33. Poynter M and Daynes R (1998) Peroxisome proliferator activated receptor alpha activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841.
34. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, and Woolf CJ (2001) Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410:471-475.
35. Schmid PC, Zuzarte-Augustin ML, and Schmid HH (1985) Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 260:14145-14149.
36. Sekiguchi F, Mita Y, Kamanaka Y, Kawao N, Matsuya H, Taga C, and Kawabata A (2004) The potent inducible nitric oxide synthase inhibitor ONO-1714 inhibits neuronal NOS and exerts antinociception in rats. Neurosci Lett 365:111-115.
37. Tao F, Tao YX, Mao P, Zhao C, Li D, Liaw WJ, Raja SN, and Johns RA (2003) Intact carrageenan-induced thermal hyperalgesia in mice lacking inducible nitric oxide synthase. Neuroscience 120:847-854.
38. Ueda N, Yamanaka K, and Yamamoto S (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276:35552-35557.
39. Urban M and Gebhart GF (1999) Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci U S A 69:7687-7692.
40. Vanegas H and Schaible H-G (2004) Descending control of persistent pain: inhibitory or facilitatory. Brain Res Brain Res Rev 46:295-309.